secwatch.observer — SEC 8-K summary
======================================

Issuer:     Virpax Pharmaceuticals, Inc. (—)
CIK:        0001708331
Form:       8-K
Filed at:   2023-12-13T23:59:59+00:00
Accession:  0001213900-23-095247
Event type: regulatory
Sentiment:  neutral
Materiality: 0.40
Item codes: 3.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Virpax regains compliance with Nasdaq periodic filing rule; bid price deficiency remains
--------------------------------------------------------------------------------

- Received Nasdaq notice confirming compliance with periodic filing requirement under Listing Rule 5250(c)(1) as of Dec 7, 2023.
- Still subject to prior bid price deficiency (Rule 5550(a)(2)) from April 2023; compliance deadline is April 8, 2024.
- No other changes to listing status or business operations disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708331/000121390023095247/0001213900-23-095247-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708331/000121390023095247/ea189951-8k_virpaxpharma.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-095247

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer